![Foto de José Luis](/img/nophoto.png)
José Luis
Pérez Gracia
Consultor Médico
Publications (166) José Luis Pérez Gracia publications
2024
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
eBioMedicine, Vol. 102
2023
-
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
Clinical Cancer Research, Vol. 29, Núm. 17, pp. 3292-3300
-
CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
Science advances, Vol. 9, Núm. 33, pp. eadf6692
-
Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Journal for immunotherapy of cancer, Vol. 11, Núm. 1
-
PSA reactivity in extracellular microvesicles to commercial immunoassays
Clinica Chimica Acta, Vol. 543
-
Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna
Annals of Oncology
-
Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials
Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77
-
Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?
Oncotarget
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for immunotherapy of cancer, Vol. 10, Núm. 5
-
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis
Cancer Letters, Vol. 529, pp. 70-84
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Journal for immunotherapy of cancer, Vol. 10, Núm. 3
2021
-
A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer
Translational Research, Vol. 233, pp. 77-91
-
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891